U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07765628) titled 'A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis' on Aug. 11.
Brief Summary: The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.
Study Start Date: Aug. 06
Study Type: INTERVENTIONAL
Condition:
Moderate to Severe Plaque Psoriasis
Intervention:
DRUG: HS-20118
Administered orally, once weekly (QW)
DRUG: Placebo
Administered orally, once weekly (QW)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Published by HT D...